Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study - PubMed
3 days ago
- #Demyelinating Attacks
- #Plasma Exchange
- #Rituximab
- Plasma exchange (PE) is used for CNS demyelinating attacks unresponsive to corticosteroids.
- Adding rituximab and IV immunoglobulins to PE (RTX-IVIG-PE) improves outcomes compared to standard PE.
- Younger age, lower pre-attack disability, and RTX-IVIG-PE treatment predict complete recovery at 6 months.
- RTX-IVIG-PE showed higher odds of improvement and complete recovery without increased adverse events.